Cumberland Pharmaceuticals Inc. (CPIX)
| Market Cap | 106.83M +260.9% |
| Revenue (ttm) | 46.29M +140.1% |
| Net Income | 68.80M |
| EPS | 4.63 |
| Shares Out | 14.98M |
| PE Ratio | 1.54 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,775 |
| Open | 6.06 |
| Previous Close | 6.12 |
| Day's Range | 6.06 - 7.39 |
| 52-Week Range | 1.85 - 9.28 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 10, 2026 |
About CPIX
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sod... [Read more]
Financial Performance
In 2025, CPIX's revenue was $44.52 million, an increase of 17.57% compared to the previous year's $37.87 million. Losses were -$2.84 million, -56.23% less than in 2024.
Financial StatementsNews
Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2026
The Apotex transaction transformed the balance sheet and redirected the business toward clinical development. Ifetroban’s DMD program is preparing for a rolling NDA review, while other pipeline programs advance.
Cumberland Pharmaceuticals Earnings release: Q3 2026
Cumberland Pharmaceuticals released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE
$100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn., Nov. 10, 2026 /PRNewswire/...
CPIX Investors Have Opportunity to Join Cumberland Pharmaceuticals Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CPIX--CPIX Investors Have Opportunity to Join Cumberland Pharmaceuticals Inc. Fraud Investigation with SBS Law.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS
NASHVILLE, Tenn., Nov. 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, a...
Cumberland plans to file NDA for ifetroban in DMD
Cumberland (CPIX) provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy, or DMD. The company ...
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
NASHVILLE, Tenn., Oct. 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products ...
Cumberland Pharmaceuticals Transcript: Study update
Phase II FIGHT DMD data showed a 5.4-point ejection-fraction difference for high-dose ifetroban versus placebo plus matched natural-history controls. FDA granted rolling review, and an NDA is planned alongside ongoing phase II programs in other indications.
Cumberland Pharmaceuticals Slides: Study update
Cumberland Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Cumberland Pharmaceuticals Press release: Study update
Cumberland Pharmaceuticals issued a press release on October 26, 2026, disclosing material business information to investors.
Cumberland announces ASSIST-SSc trial results
Cumberland (CPIX) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis, or SSc. These results support the safety and tolerabilit...
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical ...
CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet me...
CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM
NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet me...
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nas...
Cumberland Pharmaceuticals Earnings Call Transcript: Q2 2026
A major strategic transaction provided $100M in cash, enabling a pivot to clinical development and a special $1.50/share dividend. The company now focuses on advancing ifetroban programs in rare diseases, with strong financial reserves and multiple clinical milestones expected in 2026.
Cumberland Pharmaceuticals Earnings release: Q2 2026
Cumberland Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Cumberland Pharmaceuticals Quarterly report: Q2 2026
Cumberland Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, ...
Cumberland announces special dividend of $1.50 per share
Cumberland (CPIX) Pharmaceuticals Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company’s common stock. The dividend will be payable on July…
Cumberland board authorizes $5M share repurchase program
In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5M in Cumberland (CPIX) shares over time. Several Board members will also be…
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
Record Date is July 10, 2026 & Payment Date is July 31,2026 Corporate and Insider Share Purchase Initiatives to Continue NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc....
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
TORONTO, July 1, 2026 /PRNewswire/ - Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing of its previously announced strategic tr...
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on Rare Disease Pipeline NASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. ...
Cumberland shares updated FIGHT DMD trial results
Cumberland (CPIX) Pharmaceuticals shared updated results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy heart disease, at the annual Parent...